Biomea Fusion, Inc. (NASDAQ:BMEA) earns a place on our list of the top 10 stocks under $5 that could triple.
As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock. With a consensus price target of $6.00, indicating a potential upside of 415.02%, analyst sentiment remains positive toward Biomea Fusion, Inc..
On March 14, 2026, Biomea Fusion, Inc. reported positive 52-week follow-up findings from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes at the ATTD conference in Barcelona. This clinical progress serves as the foundation for analyst optimism.
Of the 267 patients assessed in the randomized, placebo-controlled trial, 163 completed at least 80% of their dosage before a clinical hold. The findings showed statistically significant declines in HbA1c, with severe insulin-deficient individuals experiencing reductions of up to 1.50% at Week 52. Efficacy was further supported by improvements in beta-cell activity and long-lasting glucose control nine months after therapy. There were no significant side effects or treatment-related discontinuations, and the therapy was well tolerated.
Biomea Fusion, Inc. formulates covalent small-molecule therapeutics aimed at treating cancers and metabolic disorders, with its primary candidate, icovamenib, targeting diabetes and BMF-219 addressing oncogenic signaling in genetically characterized tumors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Hedge Fund Resource Center